Nocturnal Use of Add-On Medications for Parkinson’s Disease: Post Hoc Analysis of the COSMOS Study
Objective: To assess nighttime use of add-on medications for Parkinson’s disease (PD) in a post hoc analysis of the COSMOS (COmedication Study assessing Mono- and…Subgroup Analyses of a Phase 3 Randomized Study of Levodopa/Carbidopa Infusion (ND0612) for Parkinson’s Patients
Objective: Evaluate efficacy and safety outcomes for different patient subgroups categorized according to their baseline characteristics from a Phase 3 study of ND0612. Background: Primary…REGENERATE-PD: A Phase 2, Randomized, Double-Blind, Surgery-Controlled Study of GDNF Gene Therapy (AAV2-GDNF; AB-1005) for Moderate Stage Parkinson’s Disease
Objective: To present the REGENERATE-PD study design: a phase 2, randomized, double-blind, surgery-controlled trial assessing efficacy and safety of intraputaminal adeno-associated virus serotype 2 containing…AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
Objective: This study developed a novel patient-independent, cost-effective AI model for detecting Freezing of Gait (FoG), using a single wearable sensor and without the need…A Randomized, Double-Blind, Placebo-Controlled Trial of a Multi-Strain Probiotic for Anxiety in Parkinson’s Disease
Objective: To evaluate the effect of a multi-strain probiotic on anxiety in patients with Parkinson’s disease (PD). Background: There is a lack of dedicated randomized…Comparing Ring and Directional Globus Pallidus Stimulation Effects on Parkinson’s Gait
Objective: This study aims to assess the possible benefits of directional stimulation for motor symptoms in Parkinson’s disease (PD) by comparing therapeutic directional versus ring…A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson’s Disease (PADOVA): Rationale, Design, and Baseline Data
Objective: To evaluate the effect on slowing motor progression and the safety of prasinezumab, a humanized monoclonal antibody targeting aggregated alpha-synuclein, in individuals with early…Distinct pattern of synaptic loss in Parkinson’s disease depression and initial findings from the Yale Ketamine PD (KET-PD) trial
Objective: To investigate synaptic loss in Parkinson's Disease depression (PDd) using PET and [11C]UCB-J (a marker for synaptic density) and present the initial blinded findings…Exploring the Neuroprotective Potential of Mushroom Extracts in Parkinson’s Disease In-Vitro Models
Objective: This study investigates the potential neuroprotective effects of several mushroom extracts in PD in-vitro models. Background: Parkinson's disease, a progressive condition, involves dysfunction or…Spray with Nasal Mucoadhesive Microspheres for Treating Parkinsonism.
Objective: Although levodopa is the preferred medication for treating Parkinson's disease, it has a very poor brain absorption and limited oral bioavailability. The goal of…
- « Previous Page
- 1
- …
- 104
- 105
- 106
- 107
- 108
- …
- 181
- Next Page »